1
|
Gubbins S, Paton DJ, Dekker A, Ludi AB, Wilsden G, Browning CFJ, Eschbaumer M, Barnabei J, Duque H, Pauszek LL, King DP. Predicting cross-protection against foot-and-mouth disease virus strains by serology after vaccination. Front Vet Sci 2022; 9:1027006. [PMID: 36532344 PMCID: PMC9751447 DOI: 10.3389/fvets.2022.1027006] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 11/18/2022] [Indexed: 08/15/2023] Open
Abstract
Serology is widely used to predict whether vaccinated individuals and populations will be protected against infectious diseases, including foot-and-mouth disease (FMD), which affects cloven-hoofed animals. Neutralising antibody titres to FMD challenge viruses correlate to protection against FMD, for vaccinated cattle that are infected with the same strain as in the vaccine (homologous protection). Similar relationships exist for cross-strain protection between different vaccine and challenge viruses, although much less data are available for these heterologous studies. Poor inter-laboratory reproducibility of the virus neutralisation test (VNT) also hampers comparisons between studies. Therefore, day-of-challenge sera (n = 180) were assembled from 13 previous FMD cross-protection experiments for serotypes O (n = 2), A (n = 10), and SAT 2 (n = 1). These were tested by VNT against the challenge viruses at the FMD FAO World Reference Laboratory (WRLFMD) and the titres were compared to challenge outcomes (protected or not). This dataset was combined with equivalent serology and protection data for 61 sera from four cross-protection experiments carried out at WRLFMD for serotypes O (n = 2), A (n = 1), and Asia 1 (n = 1). VNT results and protection outcomes were also analysed for a serotype O cross-protection experiment involving 39 cattle, where the sera were not available for retesting at WRLFMD. Three categories of association between heterologous neutralising antibody titre and heterologous protection were found (Group 1-3). The log10 reciprocal titres associated on average with 75% protection (with 95% credible limits) were: Group 1: 2.46 (2.11-2.97); Group 2: 1.67 (1.49-1.92); Group 3: 1.17 (1.06-1.30). Further cross-protection data are needed to understand the factors that underpin this variability and to develop more robust antibody thresholds. Establishing cut-off serological titres that can be used to score the adequacy of vaccine-induced immunity will facilitate the monitoring and thereby the performance of FMD vaccination in the field.
Collapse
Affiliation(s)
| | | | - Aldo Dekker
- Laboratory Vesicular Diseases, Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Lelystad, Netherlands
| | - Anna B. Ludi
- The Pirbright Institute, Pirbright, United Kingdom
| | | | | | - Michael Eschbaumer
- Institute of Diagnostic Virology, Friedrich-Loeffler-Institut, Greifswald, Germany
| | - Jamie Barnabei
- Plum Island Animal Disease Center, Greenport, NY, United States
| | - Hernando Duque
- Plum Island Animal Disease Center, Greenport, NY, United States
| | - Lisa L. Pauszek
- Plum Island Animal Disease Center, Greenport, NY, United States
| | | |
Collapse
|
2
|
Lu Z, Yu S, Wang W, Chen W, Wang X, Wu K, Li X, Fan S, Ding H, Yi L, Chen J. Development of Foot-and-Mouth Disease Vaccines in Recent Years. Vaccines (Basel) 2022; 10:1817. [PMID: 36366327 PMCID: PMC9693445 DOI: 10.3390/vaccines10111817] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 10/24/2022] [Accepted: 10/26/2022] [Indexed: 12/20/2023] Open
Abstract
Foot-and-mouth disease (FMD) is a serious disease affecting the global graziery industry. Once an epidemic occurs, it can lead to economic and trade stagnation. In recent decades, FMD has been effectively controlled and even successfully eradicated in some countries or regions through mandatory vaccination with inactivated foot-and-mouth disease vaccines. Nevertheless, FMD still occurs in some parts of Africa and Asia. The transmission efficiency of foot-and-mouth disease is high. Both disease countries and disease-free countries should always be prepared to deal with outbreaks of FMD. The development of vaccines has played a key role in this regard. This paper summarizes the development of several promising vaccines including progress and design ideas. It also provides ways to develop a new generation of vaccines for FMDV and other major diseases.
Collapse
Affiliation(s)
- Zhimin Lu
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Shu Yu
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Weijun Wang
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Wenxian Chen
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Xinyan Wang
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Keke Wu
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Xiaowen Li
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Shuangqi Fan
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Hongxing Ding
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Lin Yi
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| | - Jingding Chen
- College of Veterinary Medicine, South China Agricultural University, No. 483 Wushan Road, Tianhe District, Guangzhou 510642, China
- Guangdong Laboratory for Lingnan Modern Agriculture, College of Veterinary Medicine, South China Agricultural University, Guangzhou 510642, China
- Key Laboratory of Zoonosis Prevention and Control of Guangdong Province, Guangzhou 510642, China
| |
Collapse
|
3
|
Di Giacomo S, Bucafusco D, Schammas JM, Pega J, Miraglia MC, Barrionuevo F, Capozzo AV, Perez-Filgueira DM. Assessment on Different Vaccine Formulation Parameters in the Protection against Heterologous Challenge with FMDV in Cattle. Viruses 2022; 14:v14081781. [PMID: 36016403 PMCID: PMC9416185 DOI: 10.3390/v14081781] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 07/26/2022] [Accepted: 08/01/2022] [Indexed: 11/23/2022] Open
Abstract
Foot-and-mouth disease (FMD) remains one of the major threats to animal health worldwide. Its causative agent, the FMD virus (FMDV), affects cloven-hoofed animals, including farm animals and wildlife species, inflicting severe damage to the international trade and livestock industry. FMDV antigenic variability remains one of the biggest challenges for vaccine-based control strategies. The current study analyzed the host’s adaptive immune responses in cattle immunized with different vaccine protocols and investigated its associations with the clinical outcome after infection with a heterologous strain of FMDV. The results showed that antigenic payload, multivalency, and revaccination may impact on the clinical outcome after heterologous challenge with FMDV. Protection from the experimental infection was related to qualitative traits of the elicited antibodies, such as avidity, IgG isotype composition, and specificity diversity, modulating and reflecting the vaccine-induced maturation of the humoral response. The correlation analyses of the serum avidity obtained per vaccinated individual might suggest that conventional vaccination can induce high-affinity immunoglobulins against conserved epitopes even within different FMDV serotypes. Cross-reaction among strains by these high-affinity antibodies may support further protection against a heterologous infection with FMDV.
Collapse
|
4
|
Singanallur NB, Eblé PL, Ludi AB, Statham B, Bin-Tarif A, King DP, Dekker A, Vosloo W. A Vaccine Based on the A/ASIA/G-VII Lineage of Foot-and-Mouth Disease Virus Offers Low Levels of Protection against Circulating Viruses from the A/ASIA/Iran-05 lineage. Viruses 2022; 14:97. [PMID: 35062300 PMCID: PMC8781018 DOI: 10.3390/v14010097] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2021] [Revised: 12/14/2021] [Accepted: 12/27/2021] [Indexed: 02/01/2023] Open
Abstract
The recent emergence and circulation of the A/ASIA/G-VII (A/G-VII) lineage of foot-and-mouth disease virus (FMDV) in the Middle East has resulted in the development of homologous vaccines to ensure susceptible animals are sufficiently protected against clinical disease. However, a second serotype A lineage called A/ASIA/Iran-05 (A/IRN/05) continues to circulate in the region and it is therefore imperative to ensure vaccine strains used will protect against both lineages. In addition, for FMDV vaccine banks that usually hold a limited number of strains, it is necessary to include strains with a broad antigenic coverage. To assess the cross protective ability of an A/G-VII emergency vaccine (formulated at 43 (95% CI 8-230) PD50/dose as determined during homologous challenge), we performed a heterologous potency test according to the European Pharmacopoeia design using a field isolate from the A/IRN/05 lineage as the challenge virus. The estimated heterologous potency in this study was 2.0 (95% CI 0.4-6.0) PD50/dose, which is below the minimum potency recommended by the World Organisation for Animal Health (OIE). Furthermore, the cross-reactive antibody titres against the heterologous challenge virus were poor (≤log10 0.9), even in those cattle that had received the full dose of vaccine. The geometric mean r1-value was 0.2 (95% CI 0.03-0.8), similar to the potency ratio of 0.04 (95% CI 0.004-0.3). Vaccination decreased viraemia and virus excretion compared to the unvaccinated controls. Our results indicate that this A/G-VII vaccine does not provide sufficient protection against viruses belonging to the A/IRN/05 lineage and therefore the A/G-VII vaccine strain cannot replace the A/IRN/05 vaccine strain but could be considered an additional strain for use in vaccines and antigen banks.
Collapse
Affiliation(s)
| | - Phaedra Lydia Eblé
- Laboratory Vesicular Diseases, Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Houtribweg 39, 8221 RA Lelystad, The Netherlands
| | | | - Bob Statham
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 ONF, UK
| | | | - Donald P King
- The Pirbright Institute, Ash Road, Pirbright, Woking GU24 ONF, UK
| | - Aldo Dekker
- Laboratory Vesicular Diseases, Department of Virology and Molecular Biology, Wageningen Bioveterinary Research, Houtribweg 39, 8221 RA Lelystad, The Netherlands
| | - Wilna Vosloo
- Australian Centre for Disease Preparedness, CSIRO-Health & Biosecurity, 5 Portarlington Road, Geelong, VIC 3220, Australia
| |
Collapse
|
5
|
Emergency FMD Serotype O Vaccines Protect Cattle against Heterologous Challenge with a Variant Foot-and-Mouth Disease Virus from the O/ME-SA/Ind2001 Lineage. Vaccines (Basel) 2021; 9:vaccines9101110. [PMID: 34696216 PMCID: PMC8537456 DOI: 10.3390/vaccines9101110] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2021] [Revised: 09/21/2021] [Accepted: 09/21/2021] [Indexed: 11/17/2022] Open
Abstract
Vaccination is one of the best approaches to control and eradicate foot-and-mouth disease (FMD). To achieve this goal, vaccines with inactivated FMD virus antigen in suitable adjuvants are being used in addition to other control measures. However, only a limited number of vaccine strains are commercially available, which often have a restricted spectrum of activity against the different FMD virus strains in circulation. As a result, when new strains emerge, it is important to measure the efficacy of the current vaccine strains against these new variants. This is important for countries where FMD is endemic but also for countries that hold an FMD vaccine bank, to ensure they are prepared for emergency vaccination. The emergence and spread of the O/ME-SA/Ind-2001 lineage of viruses posed a serious threat to countries with OIE-endorsed FMD control plans who had not reported FMD for many years. In vitro vaccine-matching results showed a poor match (r1-value < 0.3) with the more widely used vaccine strain O1 Manisa and less protection in a challenge test. This paper describes the use of the O3039 vaccine strain as an alternative, either alone or in combination with the O1 Manisa vaccine strain with virulent challenge by a O/ME-SA/Ind-2001d sub-lineage virus from Algeria (O/ALG/3/2014). The experiment included challenge at 7 days post-vaccination (to study protection and emergency use) and 21 days post-vaccination (as in standard potency studies). The results indicated that the O3039 vaccine strain alone, as well as the combination with O1 Manisa, is effective against this strain of the O/ME-SA/Ind/2001d lineage, offering protection from clinical disease even after 7 days post-vaccination with a reduction in viraemia and virus excretion.
Collapse
|
6
|
Park SH, Lee SY, Kim JS, Kim AY, Park SY, Lee JH, Lee M, Kim H, Lee SI, Kang NY, Park JW, Kim SM, Park JH, Ko YJ. Scale-Up Production of Type O and A Foot-and-Mouth Disease Bivalent Vaccine and Its Protective Efficacy in Pigs. Vaccines (Basel) 2021; 9:vaccines9060586. [PMID: 34199359 PMCID: PMC8227705 DOI: 10.3390/vaccines9060586] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Revised: 05/21/2021] [Accepted: 05/28/2021] [Indexed: 11/20/2022] Open
Abstract
South Korea has experienced FMD outbreaks almost every year since 2014. Therefore, a novel local vaccine that can cover various topotypes of viruses is required. Two virus strains, O/Boeun/SKR/2017 and A/Yeoncheon/SKR/2017, were cultured up to the pilot scale based on the optimized conditions set up on the flask scale. FMDV particles (146S) of 2 µg/mL or more were obtained from the virus culture supernatant using a 100 L bioreactor. The viruses were fully inactivated using binary ethylenimine within 16 h through two inactivation cycles and mixed with an adjuvant into a bivalent vaccine (types O and A) consisting of 15 µg viruses per strain. The experimental bivalent vaccine showed a broad spectrum of high neutralizing antibody titers against heterologous viruses, including type O Cathay strain and type A Asia topotypes, except for GVII. The 50% protective dose was determined as 12.5 for O/Boeun/SKR/2017 and 15.6 for A/Yeoncheon/SKR/2017. Collectively, we expect that the bivalent vaccine could protect against FMDV types O and A circulating in South Korea and neighboring countries. To our knowledge, this is the first report demonstrating that the vaccine strains could be successfully scaled-up to a 100 L bioreactor, with the determination of its protective efficacy in pigs.
Collapse
Affiliation(s)
- Sang-Hyun Park
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Seo-Yong Lee
- Research Unit, FVC Vaccine Company, #521, 5, Hyeoksin 8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-Y.L.); (J.-H.L.); (M.L.)
| | - Jae-Seok Kim
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Ah-Young Kim
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Sun-Young Park
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Ji-Hye Lee
- Research Unit, FVC Vaccine Company, #521, 5, Hyeoksin 8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-Y.L.); (J.-H.L.); (M.L.)
| | - Mijung Lee
- Research Unit, FVC Vaccine Company, #521, 5, Hyeoksin 8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-Y.L.); (J.-H.L.); (M.L.)
| | - Hyejin Kim
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Sim-In Lee
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Na-Young Kang
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Jung-Won Park
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Su-Mi Kim
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Jong-Hyeon Park
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
| | - Young-Joon Ko
- Animal and Plant Quarantine Agency, 177 Hyeoksin-8-ro, Gimcheon-si 39660, Gyeongsangbuk-do, Korea; (S.-H.P.); (J.-S.K.); (A.-Y.K.); (S.-Y.P.); (H.K.); (S.-I.L.); (N.-Y.K.); (J.-W.P.); (S.-M.K.); (J.-H.P.)
- Correspondence: ; Tel.: +82-5491-209-08
| |
Collapse
|